Developing a new national MDMA policy: Results of a multi-decision multi-criterion decision analysis

  title={Developing a new national MDMA policy: Results of a multi-decision multi-criterion decision analysis},
  author={Jan G.C. van Amsterdam and Gjalt-Jorn Ygram Peters and Ed J M Pennings and Tom Blickman and Kaj Hollemans and Joost J Breeksema and Johannes G Ramaekers and C. W. Maris and Floor van Bakkum and Ton Nabben and Willem Scholten and Tjibbe Reitsma and Judith Noijen and Raoul Koning and Wim van den Brink},
  journal={Journal of Psychopharmacology (Oxford, England)},
  pages={537 - 546}
Background: Ecstasy (3,4-methylenedioxymethamphetamine (MDMA)) has a relatively low harm and low dependence liability but is scheduled on List I of the Dutch Opium Act (‘hard drugs’). Concerns surrounding increasing MDMA-related criminality coupled with the possibly inappropriate scheduling of MDMA initiated a debate to revise the current Dutch ecstasy policy. Methods: An interdisciplinary group of 18 experts on health, social harms and drug criminality and law enforcement reformulated the… 

Figures and Tables from this paper

Equasy revisited
  • A. Young
  • Psychology
    Journal of psychopharmacology
  • 2021
This edition of the Journal has five papers on MDMA, with fascinating papers on the association of the OPRM1 A118G polymorphism and Pavlovian-to-instrumental transfer and the clinical relevance for alcohol dependence, and therapeutic benefit with minimal physical and neurocognitive benefits from the use of MDMA-assisted psychotherapy in treatment with resistant PTSD.
Some Contributions on How to Formulate Drug Policies and Provide Evidence-Based Regulation
Although increasing amounts of the population support liberalization to some drugs, notably cannabis, in order for this to lead to actual policy change the issue of drug reform needs to be made salient to both policymakers and citizens.


A new approach to formulating and appraising drug policy: A multi-criterion decision analysis applied to alcohol and cannabis regulation.
Drug harms in the UK: a multicriteria decision analysis
Use characteristics and harm potential of ecstasy in The Netherlands
Abstract Introduction Ecstasy (MDMA) is a popular recreational drug, but its illegal production and trade in the Netherlands have developed into a serious public order and ecological problem which
The challenges in developing a rational cannabis policy
Development of a more rational cannabis policy requires better evaluations of both the health consequences of regular cannabis use and of the costs and benefits of enforcing the existing prohibition on its use.
Ranking the Harm of Alcohol, Tobacco and Illicit Drugs for the Individual and the Population
Whether the legal classification of drugs in the Netherlands corresponds with the ranking of the drugs according to their science-based ranking of harm based on the scientific state of the art is evaluated.
Ranking the harm of non-medically used prescription opioids in the UK.
European rating of drug harms
The results indicates that EU and national drug policy measures should focus on drugs with the highest overall harm, including alcohol and tobacco, whereas drugs such as cannabis and ecstasy should be given lower priority including a lower legal classification.
Inter se Modification of the UN Drug Control Conventions
Legal tensions are growing as more jurisdictions move towards legal regulation of the cannabis market in contravention of the obligation under UN drug control treaties to limit cannabis exclusively
Are ecstasy induced serotonergic alterations overestimated for the majority of users?
The findings suggest that the serotonin brain imaging literature has focused on unusually heavy ecstasy use and therefore the conclusions from these studies are likely to overestimate the extent of serotonergic alterations experienced by the majority of people who use ecstays.